MILPITAS, Calif. & FREDERICK, Md., July 8, 2026
RoosterBio and Applied StemCell (ASC) have announced a strategic partnership to develop and commercialize scalable induced pluripotent stem cell (iPSC)-based bioprocess solutions, bringing together GMP-compatible iPSC technology, engineered bioprocess media, and scalable manufacturing systems to accelerate the development of advanced cell and gene therapies. The collaboration combines Applied StemCell’s proprietary iPSC platform with RoosterBio’s expertise in cellular starting materials, bioprocess media, reagents, and advanced therapy manufacturing solutions, creating an integrated workflow that supports therapeutic developers from early-stage research through clinical and commercial manufacturing. By simplifying complex manufacturing processes and providing an end-to-end solution, the partnership aims to improve product consistency, shorten development timelines, and enable the scalable production of next-generation regenerative medicines. The companies believe the combined platform addresses one of the industry’s most significant manufacturing challenges by delivering high-quality GMP-derived starting materials together with optimized bioprocess systems designed specifically for cell therapy and regenerative medicine applications. The collaboration further reinforces both companies’ commitment to advancing innovative manufacturing technologies that accelerate the translation of breakthrough therapies from laboratory research to patients.
Integrated iPSC Bioprocess Platform Streamlines Advanced Therapy Development
The newly announced partnership delivers a comprehensive manufacturing solution that combines Applied StemCell’s GMP-enabled induced pluripotent stem cell technology with RoosterBio’s purpose-built media, reagents, and scalable bioprocess systems into a unified workflow. The integrated platform is designed to eliminate the need for therapeutic developers to source cellular starting materials, manufacturing media, process engineering expertise, and intellectual property from multiple suppliers, significantly reducing technical complexity, development costs, and commercialization risks.
Induced pluripotent stem cells have become a cornerstone technology for immunotherapy, neurodegenerative disease research, iPSC-derived mesenchymal stromal cells (iMSCs), and numerous regenerative medicine applications. As demand for these advanced therapies continues to grow, developers require manufacturing systems capable of delivering reproducible quality while supporting commercial-scale production. The combined ASC-RoosterBio solution is expected to close longstanding consistency and quality gaps that have limited iPSC development by providing a standardized, scalable manufacturing platform engineered specifically for advanced therapeutic applications.
Strategic Collaboration Strengthens the Future of Cell Therapy Manufacturing
Advertisement
Company executives emphasized that the partnership represents an important milestone for the rapidly evolving cell and gene therapy manufacturing industry. Applied StemCell contributes extensive expertise in genome engineering, proprietary TARGATT™ targeted integration technology, advanced gene editing, and iPSC engineering, while RoosterBio provides industry-leading capabilities in stem cell manufacturing, extracellular vesicle production, bioprocess development, recombinant proteins, and cGMP manufacturing solutions. Together, the companies aim to accelerate process development, improve manufacturing consistency, and support a seamless transition from laboratory research to scalable clinical production.
According to the companies, the integrated technology platform will enable therapeutic developers to reduce process development cycles, enhance manufacturing efficiency, and deliver transformational value across the advanced therapy ecosystem. As global investment in regenerative medicine, stem cell therapies, and gene editing continues to expand, scalable and standardized manufacturing platforms will play an increasingly critical role in enabling commercialization of innovative therapies. Through this strategic collaboration, RoosterBio and Applied StemCell seek to provide biotechnology companies, pharmaceutical developers, and research organizations with an end-to-end solution capable of accelerating clinical translation while supporting the growing worldwide demand for safe, effective, and commercially scalable iPSC-based therapeutic products.
Source: RoosterBio, Applied StemCell press release
